Neuromolecular Imaging and BRODERICK PROBE® nanobiosensors reveal a temporal synchrony in brain rhythms in neural transmission online with movement designs during natural physiology:Temporal asynchrony is imaged online in the same subject during pathology A rhythmic brain disrupted defines disease: Translating from animal to human
Main Article Content
Abstract
Temporal synchrony, discovered in our laboratory using Live Imaging, Neuromolecular Imaging (NMI), and the BRODERICK PROBE® reveals a distinctive rhythmic regularity between neurotransmitter synaptic release and movement frequency in the natural, physiologic state. Using this innovative nanotechnology of NMI and BRODERICK PROBE® nanobiosensors, a point-by-point temporal synchrony was imaged between the synaptic concentration of serotonin (5-HT) released from structures such as dorsal striatum A9 and ventral striatum A10 terminals, basal nucleus, and ventrolateral nucleus accumbens (vlNAcc) in concert with natural open-field behaviors such as ambulating movement and finer movements of grooming, licking, and chewing. Indeed, 5-HT synaptic concentration increased and decreased in parallel and simultaneously with the rise and fall of open-field behavior frequency. Thus, temporal synchrony occurs when the symphony of physiologic neurochemistry and behavior is uninterrupted by drugs, disease, or injury. In contrast, neurotransmitter release and movement frequency are not in concert when monitoring, for example, psychostimulant-induced behaviors produced by cocaine. After cocaine administration, NMI and BRODERICK PROBE® nanobiosensors revealed temporal asynchrony between endogenous 5-HT release at A10 terminals, basal stem nucleus, somatodendrites, and VTA and both cocaine-induced ambulations and fine movements in freely moving, male Sprague Dawley animals.
Temporal asynchrony was also seen during intraoperative, in vivo studies of neurotransmitter release in anterior temporal lobe epilepsy in a human patient. It is likely that time sensitive asynchrony occurred due to the chemical movement of neurotransmitters away from catecholamine and indoleamine neurotransmitters to excitatory neural transmission via the neuropeptide, dynorphin 1-17, that is readily imaged by NMI. NMI recordings with laminar biocompatible carbon-based BRODERICK PROBE® nanobiosensors were taken at a cortical depth of microns to less than 2 mm for 20-30 minute intervals in the epilepsy patient during resection surgery intraoperatively. Importantly, L-tryptophan (L-TP) was imaged online during the operation showing the lack of the ability of the asynchronous brain to produce 5-HT, the hallmark of the synchronous natural state of physiology. Therefore, L-TP and neuropeptides such as excitatory Dynorphins may serve as neurobiomarkers for pharmaco- and/or gene therapy for neurodegenerative processes. In this manner, temporal patterns may be used to create a dynamic data profile in the clinical setting. Although static neurotransmitter levels are currently the standard, these static parameters become more valuable when empirically studied within the context of movement rather than solely focusing on whether a neurotransmitter level has increased or decreased. Not only does this dynamic data provide a more complete portrait of the temporal harmony of physiology, but it may also be used to distinguish the intensity of disease or drug-induced temporal cacophony on specific parts of microneuroanatomy. Therefore, a rhythmic brain, disrupted, may well define brain disease.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
1. Center for Behavioral Health Statis-tics and Quality. 2016 National Sur-vey on Drug Use and Health: Detailed Tables [Internet]. 2016. [cited 16 February 2018]. Available from: https://www.samhsa.gov/ da-ta/sites/default/files/NSDUH-DetTabs-2016/NSDUH-DetTabs-2016.pdf
2. World Drug Report. Pre-Briefing to the Member States [Internet]. 2017 [16 February 2018]. Available https://www.unodc.org/wdr2017/field/WDR_2017_presentation_lauch_version.pdf
3. Di Chiara G, Imperato A. Drugs abused by humans preferentially in-crease synaptic dopamine concentra-tions in the mesolimbic system of freely moving rats. Proc Natl Acad Sci. 1988;85:5274–5278.
4. Koob GF, Bloom FE. Cellular and molecular mechanisms of drug de-pendence. Science. 1988;242:715–723.
5. Volkow ND, Wang G-J, Telang F, Fowler JS, Logan J, Childress A-R, Jayne M, Ma Y, Wong C. Cocaine Cues and Dopamine in Dorsal Stria-tum: Mechanism of Craving in Co-caine Addiction. The Journal of Neu-roscience. 2006;26(24):6583– 6588.
6. Bromfield EB, Cavazos JE, Sirven JI. An Introduction to Epilepsy [Inter-net]. 2006 [cited 16 February 2018]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK2508/
7. Broderick PA. In vivo electrochemi-cal studies of gradient effects of (SC) cocaine on dopamine and serotonin release in dorsal striatum of conscious rats. Pharmacology Biochemistry and Behavior. 1993;46(4):973-984.
8. Jacobs BL, Azmitia EC. Structure and function of the brain-serotonin system. Physiol. Rev. 1992;72:165–229.
9. Broderick PA, Phelix CF. I. Serotonin (5-HT) within dopamine reward cir-cuits signals open-field behavior II. Basis for 5-HT-DA interaction in co-caine dysfunctional behavior. Neu-roscience and Biobehavioral Reviews 1997;21(3):227-260.
10. Jacobs BL. Single unit-activity of brain monoamine-containing neurons in freely moving animals. Ann. N. Y. Acad. Sci. 1986;473:70–79. doi: 10.1111/j.1749-6632.1986.tb23604.x.
11. Jacobs BL, Fornal CA. Activity of brain serotonergic neurons in the be-having animal. Pharmacol. Rev. 1991;43:563–578.
12. Broderick PA, Doyle WK, Pacia SV, Kuzniecky RI, Devinsky O, Kolodny EH. A clinical trial of an advanced diagnostic biomedical device for epi-lepsy patients. J Long Term Eff Med Implants 2008; 18: 50. [http://dx.doi.org/10.1615/JLongTermEffMedImplants.v18.i1.480]
13. Broderick PA. Neuromolecular Imag-ing shows Temporal Synchrony Pat-terns between serotonin and move-ment within neuronal motor circuits in brain. Brain Sciences 2013; 3: 992-1012.
14. Broderick PA. Real time signal processing at the neuromolecular lev-el in the epilepsy and Parkinson’s brain. IEEE Signal Processing in Medicine and Biology Symposium, Technical Program, Saturday, De-cember 1, 2012 at the Grove School of Engineering, CCNY, in conjunc-tion with the NYU Polytechnic Insti-tute, New York.
15. Broderick PA. Noninvasive Elec-troactive Photonic Protein Sensor with Polymer Photovoltaic Optics for Memory Transduction using Organic and Inorganic Elements as Platforms. US Provisional Patent. 2015. Patent # 62/273,693. Issued.
16. Broderick PA. Noninvasive Elec-troactive Photonic Protein Sensor with Polymer Photovoltaic Optics for Memory Transduction using Organic and Inorganic Elements as Platforms. US Non-Provisional Patent. 2016. In-ternational Application Patent # PCT/US16/68879. Issued.
17. Broderick PA, Pacia SV. Identifica-tion, diagnosis, and treatment of neu-ropathologies, neurotoxicities, tu-mors, and brain and spinal cord inju-ries using electrodes with microvol-tammetry. US Patent. 2007, 2011, 2017. Patent # 2007/0026440. Issued.
18. Broderick PA. Characterizing stearate probes in vitro for the electrochemical detection of dopamine and serotonin. Brain Res. 1989; 495:115–121
19. Broderick PA. Microelectrodes and their use in cathodic electrochemical current arrangement with telemetric application. US Patent. 1995;US Pa-tent # 5,433,710, Issued.
20. Broderick PA. Microelectrodes and their use in an electrochemical ar-rangement with telemetric applica-tion. US Patent. 1999;US Patent # 5,938,903, Issued.
21. Broderick PA. Noninvasive Photonic Sensor with Polymer Memory Trans-duction using Organic and Inorganic Elements as Platforms. USPTO. 2015; USPTO Provisional Patent.
22. Broderick PA, Pacia SV. Identifica-tion, diagnosis, and treatment of neu-ropathologies, neurotoxicities, tu-mors, and brain and spinal cord inju-ries using microelectrodes with mi-crovoltammetry. USPTO. 2006; USPTO_US Patent #7,112,319, Is-sued.
23. Broderick PA, Pacia SV. Identifica-tion, diagnosis, and treatment of neu-ropathologies, neurotoxicities, tu-mors, and brain and spinal cord inju-ries using microelectrodes with mi-crovoltammetry. USPTO. 2011 ;USPTO USSN Patent #2011/13/083,810, Pending.
24. Broderick PA. Distinguishing in vitro electrochemical signatures for norepinephrine and dopamine. Neurosci Lett. 1988;95:275–280
25. Broderick PA. Cathodic Electrochemical Current Arrangement with Telemetric Application. US Patent. 1989;US Patent # 4, 883,057, Issued.
26. Broderick PA. Studies of oxidative stress mechanism using a mor-phine/ascorbate animal model and novel N-stearoyl cerebroside and lau-rate sensors. J Neural Transm. 2008;115(1):7–17
27. Broderick PA, Pacia SV, Doyle WK, Devinsky O. Monoamine neuro-transmitters in resected hippocampal subparcellations from neocortical and mesial temporal lobe epilepsy patients: in situ microvoltammetric studies. Brain Res. 2000;878:49-63
28. Broderick PA, Ho H, Wat K, Murthy V. Laurate biosensors image brain neurotransmitters in vivo: Can an an-tihypertensive medication alter psy-chostimulant behavior? Sensors. 2008; 8:4033-4061
29. Broderick PA, Pacia SV (2005) Imag-ing white matter signals in epilepsy patients: A unique sensor technology. In: Broderick PA, Rahni DN, Kolod-ny EH (ed) Bioimaging in Neurode-generation, Humana Press Inc., Springer, New Jersey; 2005. p. 199–206.
30. Broderick PA. In vivo voltammetric studies on release mechanisms for cocaine with gammabutyrolactone. Pharmacol Biochem Behav. 1991;40:969–975
31. Bradberry CW, Nobiletti JB, Elsworth JD, Murphy B, Jatlow P, Roth RH. Cocaine and cocaethy-lene: microdialysis comparison of brain drug levels and effects on do-pamine and serotonin. J Neuro-chem. 1993;60(4):1429-1435.
32. Essman WD, Singh A, Lucki I. Sero-tonergic properties of cocaine: effects on a 5-HT2 receptor-mediated behavior and on extracellular concentrations of serotonin and dopamine. Pharmacol Biochem Be-hav. 1994;49(1):107-113.
33. Hernandez L, Hoebel BG. Food re-ward and cocaine increase extracellu-lar dopamine in the nucleus accum-bens as measured by microdialysis. Life Sci. 1988;42(18):1705-1712.
34. Hernandez L, Guzman NA, Hoebel BG. Bidirectional microdialysis in vivo shows differential dopaminergic potency of cocaine, procaine and li-docaine in the nucleus accumbens us-ing capillary electrophoresis for cali-bration of drug outward diffusion. Psychopharmacology (Berl). 1991;105(2):264-8.
35. Parsons LH, Justice JB Jr. Serotonin and dopamine sensitization in the nucleus accumbens, ventral tegmental area, and dorsal raphe nucleus following repeated cocaine administration. J Neurochem. 1993;61(5):1611-9.
36. Cunningham KA, Lakoski JM. Elec-trophysiological effects of cocaine and procaine on dorsal raphe seroto-nin neurons. Eur J Pharma-col. 1988;13;148(3):457-62.
37. Pan ZZ, Williams JT. Differential actions of cocaine and amphetamine on dorsal raphe neurons in vitro. J Pharmacol Exp Ther. 1989;251(1):56-62.
38. Tuboly G, Vécsei L. Somatostatin and cognitive function in neurodege-nerative disorders. Mini Rev Med Chem. 2013;13(1):34-46.